NDAORALTABLET
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors
Pharmacologic Class:
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor
Clinical Trials (5)
Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury
Started Oct 2025
To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
Started Jul 2025
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents
Started Jan 2025
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease
Started Jan 2025
Vafseo Outcomes In-Center Experience
Started Nov 2024
Loss of Exclusivity
LOE Date
Mar 31, 2036
122 months away
Patent Expiry
Mar 31, 2036
Exclusivity Expiry
Mar 27, 2029